CRISPR-mediated correction could be considered for WD, but the hundreds of different mutations in ATP7B and their often compound heterozygous nature complicate site-specific correction with gene editing (Pöhler et al., 2020). The gene discussed is ATP7B; the disease is Wilson disease.